CT-388 Research for Type 2 Diabetes
An evidence-based overview of research examining CT-388 in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
The GLP-1/GIP dual agonist mechanism has proven effective for glycemic control with tirzepatide. CT-388 is expected to have similar glucose-lowering effects through enhanced insulin secretion and improved insulin sensitivity. A Phase 2 T2D trial (NCT06628362) is active and not yet recruiting to completion; published CT-388 glycemic data so far come from the Phase 1 trial (NCT04838405).
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CT-388 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.